Publication number: 20210401984
Abstract: Immunoprotective primary mesenchymal stems cells (IP-MSC) which episomally express immunoreactive polypeptides that specifically target a pathogen (e.g., an infectious species of virus, bacterium, or parasite) or toxin are described herein. The immunoreactive polypeptides can be, e.g., full antibodies, single-chain antibodies (ScFV), Fab or F(ab)2 antibody fragments, diabodies, tribodies, and the like). Optionally IP-MSC are trasfected to express one or more other immunomodulating polypeptides, e.g., a cytokine such as an interleukin (e.g., IL-2, IL-4, IL-6, IL-7, IL-9, and IL-12), an interferon (e.g., IFN?, IF?, or IFN?), and the like, which can enhance the effectiveness of the immunoreactive polypeptides.
Type:
Application
Filed:
September 17, 2021
Publication date:
December 30, 2021
Applicants:
THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND, AUTOIMMUNE TECHNOLOGIES, LLC
Inventors:
Robert Francis GARRY, Luis Manuel BRANCO, Bruce Alan BUNNELL, Russell B. WILSON, Samuel E. HOPKINS
Publication number: 20190282694
Abstract: Immunoprotective primary mesenchymal stems cells (IP-MSC) which episomally express immunoreactive polypeptides that specifically target a pathogen (e.g., an infectious species of virus, bacterium, or parasite) or toxin are described herein. The immunoreactive polypeptides can be, e.g., full antibodies, single-chain antibodies (ScFV), Fab or F(ab)2 antibody fragments, diabodies, tribodies, and the like). Optionally IP-MSC are transfected to express one or more other immunomodulating polypeptides, e.g., a cytokine such as an interleukin (e.g., IL-2, IL-4, IL-6, IL-7, IL-9, and IL-12), an interferon (e.g., IFN?, IFN?, or IFN?), and the like, which can enhance the effectiveness of the immunoreactive polypeptides.
Type:
Application
Filed:
May 30, 2019
Publication date:
September 19, 2019
Applicants:
THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND, AUTOIMMUNE TECHNOLOGIES, LLC
Inventors:
Robert Francis Garry, Luis Manuel Branco, Bruce Alan Bunnell, Russell B. Wilson, Samuel E. Hopkins
Patent number: 10357562
Abstract: Immunoprotective primary mesenchymal stems cells (IP-MSC) which episomally express multiple immunoreactive polypeptides that specifically target a pathogen (e.g., an infectious species of virus, bacterium, or parasite) or toxin are described herein. The IP-MSC express two or more (e.g., 2 to about 100) immunoreactive polypeptides (e.g., full antibodies, single-chain antibodies (ScFV), Fab or F(ab)2 antibody fragments, diabodies, tribodies, and the like), and optionally one or more other immunomodulating polypeptides, e.g., a cytokine such as an interleukin (e.g., IL-2, IL-4, IL-6, IL-7, IL-9, and IL-12), an interferon (e.g., IFN?, IFN?, or IFN?), and the like, which can enhance the effectiveness of the immunoreactive polypeptides.
Type:
Grant
Filed:
July 17, 2015
Date of Patent:
July 23, 2019
Assignees:
The Administrators of the Tulane Educational Fund, Autoimmune Technologies, LLC
Inventors:
Robert Francis Garry, Luis Manuel Branco, Bruce Alan Bunnell, Russell B. Wilson, Samuel E. Hopkins
Publication number: 20160129110
Abstract: Immunoprotective primary mesenchymal stems cells (IP-MSC) which episomally express multiple immunoreactive polypeptides that specifically target a pathogen (e.g., an infectious species of virus, bacterium, or parasite) or toxin are described herein. The IP-MSC express two or more (e.g., 2 to about 100) immunoreactive polypeptides (e.g., full antibodies, single-chain antibodies (ScFV), Fab or F(ab)2 antibody fragments, diabodies, tribodies, and the like), and optionally one or more other immunomodulating polypeptides, e.g., a cytokine such as an interleukin (e.g., IL-2, IL-4, IL-6, IL-7, IL-9, and IL-12), an interferon (e.g., IFN?, IFN?, or IFN?), and the like, which can enhance the effectiveness of the immunoreactive polypeptides.
Type:
Application
Filed:
July 17, 2015
Publication date:
May 12, 2016
Applicants:
AUTOIMMUNE TECHNOLOGIES, LLC, THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND
Inventors:
Robert Francis GARRY, Luis Manuel BRANCO, Bruce Alan BUNNELL, Russell B. WILSON, Samuel E. HOPKINS
Patent number: 9101597
Abstract: Immunoprotective primary mesenchymal stems cells (IP-MSC) which episomally express multiple immunoreactive polypeptides that specifically target a pathogen (e.g., an infectious species of virus, bacterium, or parasite) or toxin are described herein. The IP-MSC express two or more (e.g., 2 to about 100) immunoreactive polypeptides (e.g., full antibodies, single-chain antibodies (ScFV), Fab or F(ab)2 antibody fragments, diabodies, tribodies, and the like), and optionally one or more other immunomodulating polypeptides, e.g., a cytokine such as an interleukin (e.g., IL-2, IL-4, IL-6, IL-7, IL-9, and IL-12), an interferon (e.g., IFN?, IFN?, or IFN?), and the like, which can enhance the effectiveness of the immunoreactive polypeptides.
Type:
Grant
Filed:
March 14, 2013
Date of Patent:
August 11, 2015
Assignees:
The Administration of the Tulane Educational Fund, Autoimmune Technologies, LLC
Inventors:
Robert Francis Garry, Luis Manuel Branco, Bruce Alan Bunnell, Russell B. Wilson, Samuel E. Hopkins